Artis Klapars

This inventor holds 18 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Nucleoside Compounds. Top assignees: Merck Sharp + Dohme Corp., Massachusetts Institute of Technology, Cardiome International Ag. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Artis Klapars. Retrieved from https://idiyas.com/inventor/artis-klapars

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 3)

% Patents Active = 88.9

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 8.2

ph-index = 6

Forward Citations = 341(Granted Patents)

Location History:

Cambridge, MA (US) (2004 - 2006)
Scotch Plains, NJ (US) (2005 - 2009)
Edison, NJ (US) (2015 - 2020)

Company Filing History:

10 out of 2,405

Merck Sharp + Dohme Corp.

patents

6 out of 8,608

Massachusetts Institute of Technology

patents

1 out of 1

Cardiome International Ag

Idenix Pharmaceuticals, Inc.

Merck Sharp & Dohme LLC

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

Fluorinated Nucleotides

Phosphoramidate Compounds

Nucleoside Synthesis

Tetracyclic Heterocycles

Copper-Catalyzed Reactions

Carbon-Heteroatom Bonds

Enamides

Aminocyclohexyl Ethers

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559514 - SYNTHESIS OF FLUORINATED NUCLEOTIDES (2026-02-24),

2. 10618926 - Process for making phosphoramidate protected nucleoside compounds (2020-04-14),

3. 10597422 - Process for making chloro-substituted nucleoside phosphoramidate compounds (2020-03-24),

4. 10526363 - Substituted phosphoramidate compounds and uses thereof (2020-01-07),

5. 10251903 - Process for making nucleoside phosphoramidate compounds (2019-04-09),

6. 10214554 - Process for making chloro-substituted nucleoside phosphoramidate compounds (2019-02-26),

7. 10202401 - Process for making tetracyclic heterocycle compounds (2019-02-12),

8. 10053460 - Process for the preparation of tert-butyl 4-((2S ,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate and analogs thereof (2018-08-21),

9. 9725464 - Process for preparing tetracyclic heterocycle compounds (2017-08-08),

10. 9067955 - Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds (2015-06-30),

11. 9006460 - Process for preparing aminocyclohexyl ether compounds (2015-04-14),

12. 8932836 - Biocatalysts and methods for the synthesis of (1R,2R)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine (2015-01-13),

13. 7629470 - Formation of tetra-substituted enamides and stereoselective reduction thereof (2009-12-08),

14. 7323608 - Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds (2008-01-29),

15. 7115784 - Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds (2006-10-03),

Title: Artis Klapars: Innovator in Nucleoside Compounds

Introduction

Artis Klapars is a prominent inventor based in Edison, NJ (US), known for his significant contributions to the field of nucleoside compounds. With a total of 17 patents to his name, Klapars has made remarkable advancements in the synthesis and application of these compounds.

Latest Patents

Klapars' latest patents include a process for making phosphoramidate protected nucleoside compounds. This invention is directed towards a process for creating compounds of a specific formula, along with their salts. Another notable patent involves a process for making chloro-substituted nucleoside phosphoramidate compounds, which are particularly useful for the treatment and prophylaxis of HCV infection. This invention also encompasses compounds that serve as synthetic intermediates for producing the aforementioned compounds.

Career Highlights

Throughout his career, Klapars has worked with esteemed organizations such as Merck Sharp & Dohme Corporation and the Massachusetts Institute of Technology. His work in these institutions has allowed him to develop innovative solutions in the pharmaceutical field.

Collaborations

Klapars has collaborated with notable individuals in his field, including Stephen L. Buchwald and Fuk Y. Kwong. These collaborations have further enhanced his research and development efforts.

Conclusion

Artis Klapars stands out as a key figure in the innovation of nucleoside compounds, with a strong portfolio of patents and a history of impactful collaborations. His work continues to influence the pharmaceutical industry and contribute to advancements in medical treatments.

Profile summary based on public USPTO records.